Michael West - AGE Old Chief Executive Officer, Founder, Director
| AGEDelisted Stock | USD 0.74 0.01 1.37% |
CEO
Dr. Michael D. West, Ph. D., is Chief Executive Officer, Founder, Director of the Company. West, has devoted his entire career to unraveling the mystery of the biological clock from his scientific training with a focus on the biology of cellular aging, to his founding of Geron, to helming other successful biotechnology companies with a focus on immortal pluripotent cellular therapies, to authoring a popular book on human aging. AgeX and its clinical programs represent the culmination of his nearly three decades of research and development into the aging process. Dr. West has served as coCEO of AgeX parent company, BioTime, Inc. since 2015, and before that as CEO, starting in 2007. From 1998 to 2007, Dr. West served as CEO, President, and Chief Scientific Officer of Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma of Japan in early 2016. In 1990 Dr. West founded Geron Corporationration, which was probably the first regenerative medicine startup, with backing from VC firms from Kleiner Perkins Caufield Byers, Venrock and others. For the companys scientific team he recruited Elizabeth Blackburn, Carol Greider and Jack Szostak, who collectively went on to win the 2009 Nobel Prize in Physiology or Medicine, and for its scientific and clinical advisory board he recruited Nobel Laureates Carol Greider and James Watson, as well as Leonard Hayflick and others. While at Geron Dr. West also created the research consortium with Drs. James Thomson and John Gearhart that led to the first isolation of human embryonic stem cells. Dr. West was a member of BioTimes Board of Directors since 2002, is a Director of Asterias Biotherapeutics and was a Director of OncoCyte Corporationration from 2013 to 2016 since 2017.
| Age | 71 |
| Tenure | 8 years |
| Phone | 510 671 8370 |
| Web | https://www.agexinc.com |
Michael West Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael West against AGE Old stock is an integral part of due diligence when investing in AGE Old. Michael West insider activity provides valuable insight into whether AGE Old is net buyers or sellers over its current business cycle. Note, AGE Old insiders must abide by specific rules, including filing SEC forms every time they buy or sell AGE Old'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael West over three months ago Acquisition by Michael West of 1333 shares of Transcat subject to Rule 16b-3 | ||
Michael West over six months ago Acquisition by Michael West of 3125 shares of AgeX Therapeutics subject to Rule 16b-3 |
AGE Old Management Efficiency
The company has Return on Asset of (0.8188) % which means that on every $100 spent on assets, it lost $0.8188. This is way below average. AGE Old's management efficiency ratios could be used to measure how well AGE Old manages its routine affairs as well as how well it operates its assets and liabilities.AGE Old has 4.37 M in debt with debt to equity (D/E) ratio of 0.75, which is OK given its current industry classification. AGE Old has a current ratio of 0.19, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AGE to invest in growth at high rates of return.
Similar Executives
| Found 8 records | CEO Age | ||
| Marcio MBA | Praxis Precision Medicines | 46 | |
| Maria Palasis | Lyra Therapeutics | 59 | |
| Michael Brigham | ImmuCell | 64 | |
| Heidi MS | Invivyd | N/A | |
| Adrian Gottschalk | Foghorn Therapeutics | 49 | |
| Clay Siegall | Immunome | 64 | |
| MBA MA | Lineage Cell Therapeutics | 54 | |
| Carole MD | Larimar Therapeutics | 66 | |
Management Performance
| Return On Asset | -0.82 |
AGE Old Leadership Team
Elected by the shareholders, the AGE Old's board of directors comprises two types of representatives: AGE Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AGE. The board's role is to monitor AGE Old's management team and ensure that shareholders' interests are well served. AGE Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AGE Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| EunJae CPA, Chief Officer | ||
| Alfred Kingsley, Chairman of the Board | ||
| Judith Segall, Secretary | ||
| Michael West, Chief Executive Officer, Founder, Director | ||
| Aubrey Grey, Vice President - New Technology Discovery | ||
| Gregory Bailey, Independent Chairman of the Board | ||
| Ivan Labat, Chief Information Officer | ||
| Joanne Hackett, Interim Board | ||
| Hal Sternberg, Vice President - Research | ||
| Nafees MD, Chief Officer | ||
| Andrea Park, Chief Financial Officer | ||
| Annalisa Jenkins, Independent Director | ||
| Michael May, Independent Director |
AGE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AGE Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.82 | |||
| Operating Margin | (63.57) % | |||
| Current Valuation | 33.33 M | |||
| Shares Outstanding | 2.5 M | |||
| Shares Owned By Insiders | 75.73 % | |||
| Shares Owned By Institutions | 5.64 % | |||
| Number Of Shares Shorted | 4.47 K | |||
| Price To Earning | (5.95) X | |||
| Price To Book | 12.96 X | |||
| Price To Sales | 221.90 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in AGE Stock
If you are still planning to invest in AGE Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the AGE Old's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |